Evidence map›Paper›PMID 41885361›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Highly Active Cu

Qiu-Xu Zang, Wei-Tong Chen, Yu-Ying Shen, Zhao-Yang Wang, Kai Li, Xueli Zhao, Yanjuan Sang, Xiaoyuan Chen, Shuang-Quan Zang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qiu-Xu ZangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.
Wei-Tong ChenState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.
Yu-Ying ShenState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.
Zhao-Yang WangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.
Kai LiState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.
Xueli ZhaoState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.
Yanjuan SangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.ORCID https://orcid.org/0009-0007-8114-6077
Xiaoyuan ChenShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
Shuang-Quan ZangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Tumor Theranostic Cluster Materials, College of Chemistry, Zhengzhou University, Zhengzhou, Henan, P. R. China.

Funding

China Postdoctoral Science Foundation 2023M743167China Postdoctoral Science Foundation 2023TQ0297Henan Province Science and Technology Research and Development Joint Fund 242301420004Key Basic Research of Henan 252310420200National Natural Science Foundation of China 22301284National Natural Science Foundation of China 92356304National Natural Science Foundation of China 92461304Tianjian Laboratory of Advanced Biomedical Sciences
6 · The paper itself

Abstract

Transition metal-mediated cleavage mechanisms have emerged as an effective means to mitigate the off-target toxicity of conventional therapeutic agents. However, the utilization of non-essential metal catalysts and suboptimal catalytic efficiency often compromises their therapeutic efficacy. Given the critical role of copper in biological processes and the high catalytic activities of atomically precise copper clusters rich in Cu

Indexed as

AutophagyCopperCuproptosisImmunotherapyAnimalsHumansImmunogenic Cell DeathMiceCopperautophagy suppressioncopper clustercuproptosisICDprodrug activation

Identifiers

PMID41885361
PMCPMC13271629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.